Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Company Overview
Agile Therapeutics Inc. (AGRX) is a dedicated women's healthcare company committed to addressing the unique health needs of modern women. Specializing in advanced transdermal drug delivery and contraceptive innovation, the company has developed products that offer women a flexible alternative to daily contraceptive pills. By harnessing its proprietary Skinfusion® technology, Agile Therapeutics delivers a non-daily, once-weekly prescription contraceptive patch that provides ease of use and improved patient adherence.
Innovative Technology and Product Focus
Central to Agile Therapeutics’ approach is its commitment to transforming women’s healthcare through innovation. The company’s lead product, Twirla®, is a combined hormonal contraceptive patch formulated using state-of-the-art transdermal technology. This system is designed to support efficient drug delivery, optimize patch adhesion, and enhance wearability, ensuring that women have a reliable and convenient contraception option without the burden of daily medication regimens.
Operational Excellence and Market Position
Agile Therapeutics operates at the intersection of biotechnology and patient-centric healthcare solutions. The company’s business model is built around leveraging its proprietary technologies to develop products that directly address the healthcare needs of women. By focusing on a specific niche in the contraceptive market, Agile Therapeutics has positioned itself as a key player in advancing non-daily contraceptive methods. Its strategic focus on innovation, controlled operating expenses, and collaborative partnerships underscores its commitment to sustainability and growth within the competitive healthcare landscape.
Commitment to Quality and Patient-Centric Solutions
At its core, Agile Therapeutics is driven by an unyielding focus on quality and patient safety. The design and development of its products, including Twirla®, are underpinned by rigorous clinical research and regulatory review. The company continually refines its product offerings to ensure that women receive a safe, effective, and convenient contraceptive option that meets modern lifestyle needs while ensuring adherence to high standards of medical care.
Industry Relevance and Competitive Landscape
Operating within the broader biotechnology and pharmaceutical sectors, Agile Therapeutics distinguishes itself by targeting a specific need within women’s healthcare. In a market where patient convenience, adherence, and minimized regimen complexity are paramount, the company’s focus on non-daily delivery systems sets it apart from traditional daily pill-based contraceptives and longer-acting methods. Its innovative approach and distinct value proposition highlight its relevancy and expertise in the competitive landscape, offering investors a clear insight into its business model and operational strategy.
Frequently Asked Questions
- What is the core business of Agile Therapeutics Inc.?
Agile Therapeutics focuses on creating innovative, non-daily contraceptive solutions designed to address the unique health needs of modern women through advanced transdermal technology. - What makes Twirla® unique?
Twirla® is a once-weekly combined hormonal contraceptive patch that utilizes the proprietary Skinfusion® platform to optimize patch adhesion and provide a convenient alternative to daily pills. - How does Agile Therapeutics generate revenue?
The company’s revenue model is primarily centered on the development, manufacturing, and commercialization of its prescription contraceptive products, supported by strategic partnerships and controlled operating expenses. - What role does transdermal technology play in its products?
Transdermal technology is fundamental to Agile’s approach, enabling effective and controlled drug delivery through the skin, which enhances patient compliance and convenience. - How is the company positioned within the competitive pharmaceutical landscape?
Agile Therapeutics differentiates itself by focusing on patient-centric, non-daily contraceptive solutions that fill a gap in women’s healthcare, thereby securing a niche within the broader biotech and pharmaceutical sectors. - What are the key advantages of Agile’s business model?
The company’s model leverages proprietary technology for innovative product development, emphasizes operational efficiency, and builds strategic partnerships to enhance market reach and sustainability.
Agile Therapeutics (Nasdaq: AGRX) has entered a securities purchase agreement for a sale of 2,425 Series A and Series B convertible preferred shares, along with Series A and B warrants, expected to raise approximately $4.85 million. Each preferred share is priced at $1,000 with a conversion price of $0.20. The Series A and B warrants allow purchases of up to 24,250,000 shares at an exercise price of $0.26. The company plans to utilize proceeds for working capital and will seek shareholder approval for a reverse stock split.
Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced that CEO Al Altomari will participate in two investor conferences. The first is the Oppenheimer 32nd Annual Virtual Healthcare Conference on Thursday, March 17, 2022, at 2:00 p.m. ET, featuring a fireside chat. The second is the Maxim Group and M-Vest 2022 Virtual Growth Conference, with a live panel discussion titled Advances in Women’s Health, from Clinical to Commercial, scheduled for Monday, March 28, 2022, at 3:00 p.m. ET. More information is available on their website.
Agile Therapeutics (Nasdaq: AGRX) plans to release its fourth quarter and full year 2021 financial results on March 30, 2022, after the market closes. A live conference call will follow at 4:30 p.m. ET, during which the company will discuss its results and provide business updates. Interested investors can access the call via telephone or through a webcast available on the company's investor relations page. This announcement highlights Agile Therapeutics' commitment to transparency and investor engagement.
On January 10, 2022, the DOL, HHS, and Treasury issued guidance enhancing women's access to FDA-approved contraceptive products, reaffirming compliance with the Affordable Care Act. The HRSA updated Women's Preventative Services Guidelines, effective for plan years beginning 2023, mandating coverage of all FDA-approved contraceptives at no cost. Agile Therapeutics supports these guidelines, emphasizing the importance of personalized contraceptive access. The company’s product, Twirla®, a non-daily contraceptive patch, is designed to meet women's diverse needs.
Agile Therapeutics (Nasdaq: AGRX) announced a strategic alliance with Afaxys Pharma to promote Twirla®, a transdermal contraceptive system. This partnership aims to enhance access to Twirla for patients in the U.S. family planning community, benefiting over 31 million Americans who rely on community health centers. Afaxys, a leader in public health, will help ensure Twirla is affordable and widely available. Twirla is indicated for women with a BMI < 30 kg/m2 and is designed for weekly use as a non-invasive contraceptive option.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that CEO Al Altomari will present at the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 7:30 a.m. ET. The presentation will be live-streamed and accessible via the investor relations section of Agile's website. Agile Therapeutics focuses on women's healthcare, offering non-daily contraceptive options, including their product Twirla, which utilizes proprietary transdermal patch technology. For further details, visit www.agiletherapeutics.com.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that its Chairman and CEO, Al Altomari, will present at two upcoming conferences: the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022, and the Biotech Showcase from January 10-12, 2022.
The presentations will be available on-demand, with the H.C. Wainwright presentation starting at 7:00 a.m. ET on January 10, and the Biotech Showcase presentation at 11:00 a.m. ET on the same day. Details can be found in the investor relations section of Agile Therapeutics' website.
Agile Therapeutics (Nasdaq: AGRX) reported a strong third quarter for 2021, seeing a 61% increase in cycles of Twirla dispensed, totaling 9,747. Total prescriptions surged by 47% to 7,374, driven by new prescribers and refills, which rose by 86%. The company partnered with Pandia Health for telehealth access and secured Twirla's placement on California's Medi-Cal preferred drug list, benefiting 15 million beneficiaries. Despite a net loss of $16.8 million, Agile anticipates increased marketing spend to drive growth, with cash reserves reported at $14.7 million.
Agile Therapeutics (Nasdaq: AGRX), a women's healthcare company, is set to announce its third quarter 2021 financial results after market close on November 2, 2021. The live conference call will take place at 4:30 p.m. ET, and will be accessible via dial-in or webcast. Investors are encouraged to log in early to participate. Agile is known for its product Twirla, a non-daily contraceptive patch.
Agile Therapeutics, Inc. (Nasdaq: AGRX) has expressed strong support for Congressional Committee leaders advocating for the enforcement of the Affordable Care Act (ACA) concerning women's access to contraceptives. The company's CEO, Al Altomari, emphasized the importance of women having the right to make personal choices regarding contraception in consultation with healthcare providers. Agile Therapeutics recognizes the efforts of the Family Planning Coalition and its members in pushing for improved access to necessary birth control methods.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
What is Agile Therapeutics Inc.?
How does Twirla® differ from traditional contraceptives?
What is the significance of the Skinfusion® platform?
What market need does Agile Therapeutics address?
How is Agile positioned within the biotechnology sector?
What are the core elements of Agile’s business model?
